Persona Ti-Nidium Post-Market Clinical Follow-up
← catalyst calendarNCT04817969 · readout ≤ 2,842 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
240estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-01 | actual | When the study began enrolling |
| Primary completion | May 2034 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Knee Pain Chronic
- Osteoarthritis
- Rheumatoid Arthritis
- Traumatic Arthritis
- Polyarthritis
- Varus Deformity
- Valgus Deformity
- Flexion Deformity of the Knee
- Avascular Necrosis
- Patellofemoral Osteoarthritis
Intervention
- Device: Zimmer Biomet Persona Ti-Nidium Total Knee System
Primary outcome
what the primary-completion date above is the date OFOxford Knee Score (OKS)
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed